title: Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.
abstract: Vincristine pharmacokinetic, tumour uptake and therapeutic characteristics were investigated here in order to elucidate the processes underlying the enhanced efficacy observed for vincristine entrapped in small (120 nm) distearoylphosphatidylcholine/cholesterol liposomes. Plasma vincristine levels after intravenous (i.v.) injection are elevated more than 100-fold in the liposomal formulation compared with free drug in tumour-bearing as well as non-tumour-bearing mice over 24 h. Biodistribution studies demonstrate that the extent and duration of tumour exposure to vincristine is dramatically improved when the drug is administered i.v. in liposomal form. Specifically, 72 h trapezoidal area under the curve values for liposomal vincristine in the murine L1210 ascitic and B16/BL6 solid tumours are 12.9- to 4.1-fold larger, respectively, than observed for free drug. Similar to previous results with the L1210 model, increased drug delivery to the B16 tumour results in significant inhibition of tumour growth, whereas no anti-tumour activity is observed with free vincristine. Comparisons of drug and liposomal lipid accumulation in tumour and muscle tissue indicate that the enhanced efficacy of liposomal vincristine is related predominantly to drug delivered by liposomes to the tumour site rather than drug released from liposomes in the circulation. Consequently, improvements in liposomal vincristine formulations must focus on factors that increase uptake of liposomes into tumour sites as well as enhance liposomal drug retention in the circulation.
authors.affiliation: British Columbia Cancer Agency, Division of Medical Oncology, Vancouver, Canada.
authors.forename: L D
authors.initials: LD
authors.lastname: Mayer
authors.forename: D
authors.initials: D
authors.lastname: Masin
authors.forename: R
authors.initials: R
authors.lastname: Nayar
authors.forename: N L
authors.initials: NL
authors.lastname: Boman
authors.forename: M B
authors.initials: MB
authors.lastname: Bally
mesh_terms: D000818:Animals; D004337:Drug Carriers; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000378:metabolism; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D009368:Neoplasm Transplantation; D014018:Tissue Distribution; D014750:Vincristine / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D004337:Drug Carriers; D014750:Vincristine